

Anti-D immunoglobulin**Section**

Human immunoglobulins

- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

Maternal care for red cell antibodies

Rh incompatibility reaction

Anti-rabies immunoglobulin**Section**

Human immunoglobulins

- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

Rabies

Anti-tetanus immunoglobulin**Section**

Human immunoglobulins

- Parenteral > General injections > IM: 500 IU in vial

Indications

Tetanus

C1 esterase inhibitor**Section**

Human immunoglobulins

- Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

Hereditary angioedema

Coagulation factor IX complex**Section**

Coagulation factors

Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

Coagulation factor IX, plasma-derived

Section

Coagulation factors

- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

Coagulation factor IX, recombinant

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia B

Coagulation factor VIII, plasma-derived

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Coagulation factor VIII, recombinant

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia A

Cryoprecipitate (native)

Section

Blood and blood components

Indications

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Obstetric haemorrhage

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Haemophilia A

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Von Willebrand disease

Cryoprecipitate (pathogen-reduced)

Section

Blood and blood components

- Injection: frozen liquid in bag or lyophilized powder in vial containing:
 - > 50 IU Factor VIII
 - > 100 IU vWF
 - > 140 mg clottable fibrinogen per unit

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Obstetric haemorrhage

Haemophilia A

Von Willebrand disease

Dextran 40

Section

Plasma substitutes

- .

Indications

Hypovolaemia

Dextran 70

Section

Plasma substitutes

- Parenteral > General injections > IV: 6% injectable solution

Indications

Hypovolaemia

Fresh-frozen plasma

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Normal immunoglobulin

Section

Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

Platelets

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Polygeline

Section

Plasma substitutes

- Parenteral > General injections > IV: 3.5% injectable solution
- Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to **dextran 70** for

Hypovolaemia

Hypovolaemia

Red blood cells

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Whole blood

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

